Sanofi-Aventis S.A. ADR
46 AVENUE DE LA GRANDE ARMEEPARIS I0 75017
P: 33-1-53-77-44-00
F: +33 153774303
http://www.sanofi.com
Sectors & Indices
Sector
Industry
Employees
Profile
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Key Executives
Name | Title |
---|---|
Olivier Charmeil | Executive VP, Divisional |
Paul Hudson | CEO/Director |
Jean-Baptiste Chasseloup De Chatillon | CFO/Executive VP |
Natalie Bickford | Executive VP/Other Executive Officer |
Julie Van Ongevalle | Executive VP, Divisional |
Thomas Triomphe | Executive VP, Divisional |
Brendan O'Callaghan | Executive VP, Divisional |
Roy Papatheodorou | Executive VP/General Counsel |
Madeleine Roach | Executive VP, Divisional |
Emmanuel Frenehard | Executive VP/Other Executive Officer |
Brian Foard | Executive VP, Divisional |
Houman Ashrafian | Executive VP/Other Corporate Officer |